Vaccination of Balb/c mice against experimental visceral leishmaniasis with the GP36 glycoprotein antigen of Leishmania donovani

Vaccine
E Paraguai de SouzaClarisa B Palatnik de Sousa

Abstract

Leishmania donovani GP36 glycoprotein is the main antigen of the FML Fucose Mannose Ligand (FML) complex specifically recognized by sera of kala-azar human patients. The GP36 was isolated by chemical elution + sonication and used for Balb/c mouse vaccination in combination with saponin, by the s.c. route, inducing a strong and specific protective effect against experimental visceral leishmaniasis shown by the increase of: specific IgG antibodies (82.6%), mainly IgG2a, the delayed type of hypersensitivity to promastigote lysate (37.8%, P < 0.001), the in vitro cellular proliferative response to GP36 of ganglia lymphocytes (53.5%, P < 0.005) and the decrease of liver parasite burden (68.1%, P < 0.025). Saponin treated controls reacted significantly differently from GP36 vaccinated animals at all the assayed variables (P < 0.05). GP36 induced significant protection against murine visceral leishmaniasis at concentrations commonly used for vaccination with recombinant antigens.

References

Aug 15, 1991·Proceedings of the National Academy of Sciences of the United States of America·A CruzS M Beverley
Mar 1, 1989·The Journal of Clinical Investigation·E M CarvalhoW D Johnson
Apr 8, 1985·Journal of Immunological Methods·M P WoodwardR A Bloodgood
Dec 1, 1987·Proceedings of the National Academy of Sciences of the United States of America·M J McConvilleE Handman
Dec 1, 1986·International Journal of Epidemiology·C M AntunesJ B Vieira
Jan 1, 1984·International Archives of Allergy and Applied Immunology·M T ScottL Chedid
Oct 24, 1995·Proceedings of the National Academy of Sciences of the United States of America·R G TitusS M Beverley
Jul 1, 1995·Transactions of the Royal Society of Tropical Medicine and Hygiene·C B Palatnik-de-SousaR Borojevic
Jan 1, 1995·The Journal of Infectious Diseases·W BrittC Kensil
Dec 1, 1994·Vaccine·D Xu, F Y Liew
Feb 1, 1994·Molecular and Biochemical Parasitology·A E SouzaJ C Mottram

❮ Previous
Next ❯

Citations

Mar 19, 2002·Molecular and Biochemical Parasitology·Débora M SantanaDavid A Campbell
May 15, 2003·Vaccine·Carolina de Oliveira MendesClarisa Beatriz Palatnik de Sousa
Oct 31, 2003·Vaccine·Wania Renata SantosClarisa Beatriz Palatnik-de-Sousa
Apr 11, 2003·Current Opinion in Infectious Diseases·Peter C Melby
Dec 24, 2002·Infection and Immunity·Saeed AhmedDiane McMahon-Pratt
Feb 4, 2016·Human Vaccines & Immunotherapeutics·Elissa M HudspethMaria Elena Bottazzi
Jul 31, 2008·Expert Review of Vaccines·Clarisa B Palatnik-de-SousaGulnara P Borja-Cabrera
Apr 11, 2015·Journal of Immunological Methods·Keerti Jain, N K Jain
May 28, 2011·International Immunopharmacology·Rajeev Nagill, Sukhbir Kaur
Jul 16, 2015·Clinical & Translational Immunology·Rhea N ColerSteven G Reed
May 22, 2010·Trends in Parasitology·Alexandre B ReisJavier Moreno
Feb 2, 2013·Brazilian Journal of Medical and Biological Research = Revista Brasileira De Pesquisas Médicas E Biológicas·C Teixeira, R Gomes
Aug 15, 2017·Journal of Biomedical Materials Research. Part B, Applied Biomaterials·Qian WangMichael J Heffernan
Feb 9, 2020·Tropical Medicine & International Health : TM & IH·Rita Velez, Montserrat Gállego
Oct 23, 2019·Vaccines·Shubhranshu ZutshiBhaskar Saha
Mar 27, 2020·Frontiers in Immunology·Clarisa Beatriz Palatnik-de-Sousa, Dirlei Nico
Mar 23, 2017·Frontiers in Immunology·Micheli Luize Barbosa SantosClarisa Beatriz Palatnik-de-Sousa

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allergy and Asthma

Allergy and asthma are inflammatory disorders that are triggered by the activation of an allergen-specific regulatory t cell. These t cells become activated when allergens are recognized by allergen-presenting cells. Here is the latest research on allergy and asthma.